Tularemia Market Overview
Tularemia, also called rabbit or deer fever, is an infectious disease caused by the bacteria Francisella tularensis and affects the eyes, skin, lymph nodes and lungs. Animals such as rodents, rabbits, and hares are the prime carriers of the disease to humans although Tularemia also infects sheep, birds, dogs, and cats. Direct exposure to airborne infections, insect and animal bites, is the prime mode of transmission. Ulceroglandular tularemia is the most common Tularemia infection with symptoms such as swollen lymph glands, light sensitivity, headache, fever, chills, eye swelling, fatigue, pain, diarrhea, pneumonia and others. Serious complications include enlarged spleen and liver, brain, spinal cord and bone infection, pericarditis, which may lead to death.
The global Tularemia market size is witnessing a downturn owing to falling incidence of Tularemia. The Tularemia market however perceives a growing intensity of drug treatment and detection owing to growing healthcare expenditure, growing exposure to causative agents and expanding healthcare and diagnostics. Tick bite is the leading causative carrier for Tularemia.
According to Market Research Future (MRFR), the global Tularemia market is expected to garner a valuation of USD 200.0 MN by the end of 2023. The Tularemia Market is anticipated to reach USD 482.5 Million by 2030 at 5.3% CAGR during the forecast period 2022-2030.
Growing tourism and game, growing exposure to bush meat and animals is expected to drive the global Tularemia market. Tourism to certain states such as Arkansas, Missouri and Oklahoma are another driver of the Tularemia market owing to the concentration of ticks and animals in these locations.
Laboratory workers are another group owing to greater exposure to the causative agent. Activities such as gardening, construction are other drivers of the tularemia market as is eating undercooked or bush meat of an animal infected by Turalemia or drinking contaminated water. Additional factors that are substantiating the market growth include the lack of elasticity of treatment and the growing per capita income. According to Centers for Disease Control and Prevention (CDC), Tularemia has a mortality ranging from 2% to 24% depending on the causative organism strain. Antibiotics used in the treatment of Tularemia are streptomycin, doxycycline, gentamicin, and ciprofloxacin.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/4120
Global Tularemia Market – Segments
The report is segmented into five dynamics to widen the scope of understanding.
By Types : Ulceroglandular Tularemia, Glandular Tularemia, Oculoglandular Tularemia, Oropharyngeal Tularemia, Pneumonic Tularemia, among others.
By Diagnosis : Microscopy, Immunochemistry, among others.
By Drugs : Streptomycin, Gentamicin, Doxycycline, Ciprofloxacin, among others.
By End-use : Hospitals and Clinics, Academic and Research Centres, among others.
By Regions : North America, Europe, Asia Pacific, and the Rest-of-the-World.
Global Tularemia Market – Regional Analysis
North America dominates the global Tularemia market with the largest market share owing to large concentration of Tularemia in the U.S. states such as Arkansas, Missouri, Dakota, and Oklahoma. Factors such as large healthcare expenditure and excellent reimbursement are factors driving the growth of the U.S. market. In 2017, 239 cases of Turalemia were reported in the U.S. Moreover, the well-established healthcare sectors and large per capita income in the U.S. provide a large demand impetus to the growth of the market in the region.
The Tularemia market in Europe is dominated by the states of Germany, Poland and Nordic states. The proliferating healthcare industry and large number of players in the region are other drivers of the European Turalemia market growth.
The Asia Pacific Tularemia market is an under developed market with a large potential. Growing pharmaceuticals manufacturing base and growing human and animal confrontation is driving a large growth of the regional market.
Global Tularemia Market – Competitive Landscape
The Tularemia market is a highly fragmented and competitive due to the presence of several big and small players. The market is commoditised and there is an intense pressure on pricing resulting in low returns on investment. The market is almost completely generic which is further constraining its value growth.
Lack of safe, effective vaccines is another constraint against tularemia. However, research and development on live attenuated vaccines is being conducted and is likely to be approved which may drive a large and faster market uptake.
Major Players:
Players leading the global Tularemia market include Bayer AG, Cipla Inc., Zydus Cadila, Nicholas Piramal, Alkem, Lupin Limited, Ranbaxy Laboratories, Dr. Reddy's Lab, Glaxo Smithkline, Glenmark Pharmaceuticals, Pfizer Inc. among others.
Industry/ Innovation/ Related News:
January 19, 2018 ---- Pharma major Lupin launched its Doxycycline Hyclate 100 mg Tablet, in the U.S. after it received approval from the Food and Drug Administration. The tablet is a generic of Pfizer's Vibra-Tablets used in the treatment of infections caused by Turalemia. With this launch lupin is expected to tap in the approximately USD 144 million sales in the U.S.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/tularemia-market-4120
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
